Bone and Joint Infections

The following advice applies to acute osteomyelitis and septic arthritis caused by haematogenous spread.  It does not apply to infection by contiguous spread (e.g. related to chronic ulcers or trauma), to chronic infections, or where prosthetic material is present.

The following advice is for empiric therapy.  Definitive therapy should be discussed with an infection specialist or paediatrician.  It should usually be guided by joint aspirate or bone biopsy which should be taken before antibiotics are instituted where possible.  For osteomyelitis and septic arthritis, consider referral to Outpatient Parenteral Antimicrobial Therapy (OPAT) service.  Sodium fusidate must be avoided if the patient has been prescribed a statin due to increased risk of rhabdomyolysis.

SEEK ORTHOPAEDIC AND INFECTION SPECIALIST ADVICE EARLY

For glossary of terms see Glossary

Drug details

Osteomyelitis
Staph aureus is the most common pathogen in children and adults

IV flucloxacillin 2g 4 times daily

4 to 6 weeks minimum with regular review. For childhood osteomyelitis, consider early oral switch. Choice of oral antibiotic should be individualised.

If penicillin allergy:

IV Vancomycin - refer to NHS Highland vancomycin dosing guidelines

4 to 6 weeks minimum with regular review. For childhood osteomyelitis, consider early oral switch.  Choice of oral antibiotic should be individualised.

Child 

See empirical antibiotic therapy poster

Septic arthritis
Staph aureus and beta-haemolytic streptococci are the commonest pathogens. Seek Microbiology advice if at risk of sexually transmitted disease

IV Flucloxacillin 2g 4 times daily

4 weeks. Consider possible IV to oral switch after 2 weeks.

Staph aureus requires 3 weeks

If penicillin allergy or if MRSA is known or suspected

IV vancomycin - refer to NHS Highland vancomycin dosing guidelines

4 weeks. Consider possible IV to oral switch after 2 weeks.

Staph aureus requires 3 weeks

Child

See empirical antibiotic therapy poster

 

Last reviewed: 30 September 2018

Next review: 30 September 2020

Author(s): Antimicrobial management team

Approved By: TAM Subgroup of ADTC

Reviewer Name(s): Area Antimicrobial Pharmacist

Document Id: AMT146